HEARTCARE-B (06609) jumped more than 6%, rising 6.21% to HK$59.9 as of press time, with trading volume reaching HK$17.38 million.

The company released its 2025 interim results, reporting revenue of RMB 186 million, representing a 44.4% year-on-year increase. Gross profit reached RMB 127 million, up 53.9% compared to the same period last year. Net profit attributable to shareholders totaled RMB 50.94 million, marking a turnaround from losses in the previous year.

According to the announcement, these improvements were primarily driven by increased revenue from newly launched hemorrhagic stroke treatment devices, rising sales volumes of ischemic stroke treatment devices and other hemorrhagic stroke treatment equipment, as well as a decline in the company's overall expense ratio.

Additionally, the company continues to advance its neuro-intervention business toward differentiated treatment devices. Sales volumes of ischemic stroke treatment devices and other access devices increased by 38.3% and 29.2%, respectively.

Revenue generated from hemorrhagic stroke treatment devices increased by approximately RMB 37.7 million compared to the same period in 2024, mainly attributed to the launch of new devices.